Alteogen Inc. Alteogen Inc.

Alteogen Inc.

196170

株式のランク #1844
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
株価
$165.61
時価総額
$11.53B
変化(1日)
4.13%
変化(1年)
-46.48%
国
KR
取引 Alteogen Inc. (196170)

カテゴリー

Healthcare
Alteogen Inc.(196170)のP/S比率
October 2026 時点のP/S比率 TTM: 57.65
Alteogen Inc. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 57.65 です。2023 年末時点でのP/S比率は 48.97 でした。
Alteogen Inc. の P/S 比率の履歴(2012 ~ 2026)
各年末時点のP/S比率
年 P/S比率 変化
2026 (TTM) 57.65 -63.93%
2024 159.83 226.37%
2023 48.97 -30.53%
2022 70.50 -28.71%
2021 98.89 -16.64%
2020 118.63 287.21%
2019 30.64 7.56%
2018 28.48 18.57%
2017 24.02 -15.48%
2016 28.42 -42.35%
2015 49.30 215.78%
2014 15.61 51.19%
2013 10.33 -17.58%
2012 12.53 0.00%
同業他社のP/S比率
企業 P/S比率 P/S比率の差 国
10.02 -82.61%
US
40.55 -29.66%
US
3.96 -93.13%
AU
- -
CH
10.15 -82.40%
NL